RxDoctor Payments Data

Nayda Kubski, MD

Psychiatry · West Palm Beach, FLNPI 1194802132

Payments from drug & device makers

$681in general payments, 2019–2025

Across 18 payments — averaging $37.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$285
  • Teva Pharmaceuticals USA, Inc.$123
  • Otsuka America Pharmaceutical, Inc.$103
  • Vanda Pharmaceuticals Inc.$84
  • Neurocrine Biosciences, Inc.$38
  • Takeda Pharmaceuticals U.S.A., Inc.$33
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$64895%
  • Education$335%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$681 in reported general payments places this provider in the 55th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$67,047
Medicare patients
131
Services billed
965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide69$47,716
ProzacFluoxetine Hcl28$18,631
VyvanseLisdexamfetamine Dimesylate19$7,318
Adderall XrDextroamphetamine/Amphetamine18$3,985
Desvenlafaxine Succinate ErDesvenlafaxine Succinate66$3,856
Quetiapine Fumarate149$3,487
Aripiprazole85$3,086
Paliperidone ErPaliperidone20$3,017
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine98$2,978
Venlafaxine Hcl ErVenlafaxine Hcl70$2,973
Duloxetine Hcl104$2,854
Alprazolam282$2,546
Clonazepam230$2,350
Dextroamphetamine Sulfate48$2,269
Lamotrigine135$1,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$33$55,03488 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →